Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POET-2: Altropane for Diagnosis of Parkinsonian Syndromes
NCT00724906Phase 3Unknown
- Sponsor
- Alseres Pharmaceuticals, Inc.
- Start
- Jul 2010
- Primary completion
- Jul 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label trial of altropane in parkinsonian syndromes (2 arms), sponsored by Alseres Pharmaceuticals, Inc. Primary endpoint: Diagnostic accuracy of 123 I-ALTROPANE® at 7 months. Status: unknown.
02
Drugs
altropane
03
Conditions
parkinsonian syndromes
Beyond the preview
Go deeper on NCT00724906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00724906.